Thetis Pharmaceuticals LLC and Harvard Medical School have presented data on the stable salt chelate of Resolvin E1, TP-317, for the potential treatment of immune checkpoint inhibitor (ICI)-resistant and sensitive tumors. TP-315 is an activator of ChemR23, a receptor expressed on immune cells in the tumor microenvironment. In vivo murine models of lung, melanoma (B16F10) and pancreatic (Panc2-H7) tumors were used to investigate TP-317 monotherapy and in combination with ICI.